Agenus secures Armenian clearance for botensilimab-balstilimab pair as it eyes Phase 3 start

Agenus has obtained its first regulatory clearance for botensilimab and balstilimab, from Armenia's Ministry of Health. The company disclosed the decision on 5 November 2026 alongside its third-quarter results. The drugs will carry the brand names Botvymo (botensilimab) and Evamplix (balstilimab).

The combination is cleared for adults with microsatellite-stable metastatic colorectal cancer who have already received treatment and who have no active liver metastases. Microsatellite-stable tumours are the segment of bowel cancer that has historically responded poorly to immunotherapy, which is why the label is of interest to those following the class (context, not drawn from the Agenus disclosure).

What the approval is worth is unclear. The material available does not cover the regulatory route Armenia used, any conditions or post-authorisation commitments, pricing, a launch date, or a commercial partner. No revenue expectations were given, and no approval in the US or EU has been reported.

Agenus also said its Phase 3 ROBBIN trial in high-risk Stage II/III microsatellite-stable colon cancer is on course to dose its first patient in the first quarter of 2027. The company points to peer-reviewed Phase 2 results from the NEST and UNICORN studies, in which about 30% of patients had a pathologic complete response. That would move the programme into an earlier disease setting than the one covered by the Armenian label.